Current role
Biotechnology · Healthcare
Board Member, CEO
2023-10-30–present
Charles Wu
Board Member
Gyre Therapeutics, Inc. (GYRE)Equibles does not estimate personal net worth.
Get an email with a short summary when Gyre Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get GYRE alertsAbout Charles Wu
Charles Wu is recorded as Board Member and CEO at Gyre Therapeutics, Inc. (GYRE) since October 30, 2023. Gyre Therapeutics, Inc. reported in an 8-K filed December 15, 2023 that Charles Wu resigned as member of the board of directors, effective January 15, 2024. Gyre Therapeutics, Inc. reported in an 8-K filed December 15, 2023 that Charles Wu retired as Chief Executive Officer, effective January 15, 2024. Gyre Therapeutics, Inc. reported in an 8-K filed October 30, 2023 that Charles Wu was appointed Chief Executive Officer, effective October 30, 2023. Equibles holds 4 filed executive changes naming Charles Wu; each is listed under recent activity with its source filing. The proxy statement of Gyre Therapeutics, Inc. reports total compensation of $15,350 for Charles Wu in fiscal 2024, including a base salary of $12,500. Disclosed compensation is on record for 3 fiscal years. Gyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gyre Therapeutics, Inc. includes Dr. Han Ying (CEO), Dr. Ying Luo (CEO and Board Member), Ping Zhang (CEO and Board Member) and 7 others.
“Dr. Charles Wu also resigned as a member of the board of directors of the Company and as a member of the board of directors of Beijing Continent Pharmaceuticals Co., Ltd., of which the Company holds an indirect controlling interest, each effective on January 15, 2024.”
“On December 13, 2023, Gyre Therapeutics, Inc. (the "Company") appointed Dr. Han Ying as the Company's Chief Executive Officer, effective January 15, 2024, to succeed Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.”
Affiliation history
-
Current
2023-10-30–present
-
Current
2023-10-30–present
-
2023-10-30–2024-01-15
-
Start not stated–2024-01-15
Company network
Leadership on record at Gyre Therapeutics, Inc.
- Dr. Han Ying CEO
- Dr. Ying Luo CEO, Board Member
- Ping Zhang CEO, Board Member
- Ying Luo CEO, Board Member
- Ying Luo, Ph.D. CEO, Board Member
- Augustine Lawlor Chairman, Board Member
- Songjiang Ma Chairman, Board Member
- Clinton Musil CFO
- Fletcher Payne CFO
- Ruoyu Chen CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Gyre Therapeutics, Inc. (GYRE) | Former Chief Executive Officer | $12,500 | $15,350 |
| 2023 | Gyre Therapeutics, Inc. (GYRE) | Former Chief Executive Officer | $106,152 | $106,152 |
| 2022 | Gyre Therapeutics, Inc. (GYRE) | Chief Executive Officer | $78,347 | $78,347 |